6Looney RJ, Anolik J, Sanz L B cell as therapeutic targets rheumalic diseases. Current opinion in rheumatology, 2004,16 (3) : 180 - 185.
7Ames PR,Tommasino C, Fossati G, et al. Liraileal effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome. Ann Hematol,2007,86 ( 3 ) :227 - 228.
8Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant churg - strauss syndrome. AnnRheum Dis,2006,65 (8) :1116-1117.
7Mattern J, Volm M. Multiple pathway drug- resistance(review) [ J ]. Int J Oncol,1993,2(4) :557 -61.
8Juliano R L, Ling V. A surface glycoprotein modulating drug permea- bility in Chinese hamster ovary cell mutants [ J ] . Biochem Biophys Acta, 1976,455 ( 1 ) : 152 - 62.
9Yan XU, Feng ZHI, Guangming X L, et al. Overcoming muhidrug - re- sistance in vitro and in vivo using the novel P - glycoprotein inhibi- tor1416[J]. Biosci,2012(32) : 559 -566.
10Zunino SJ, Storms DH, Ducore JM. Novel in vivo model of inducible multi - drag resistance in acute lymphoblastic leukemia with chromo- somal translocation t ( 4 ;11 ) [ J ]. Cancer Lett, 2010, 296 ( 1 ) : 49 - 54.
